China Universal Asset Management Company’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$841K Sell
14,800
-5,025
-25% -$223K 0.05% 220
2026
Q1
$589K Buy
19,825
+4,746
+31% +$142K 0.04% 246
2025
Q4
$576K Sell
15,079
-546
-3% -$17.8K 0.04% 244
2025
Q3
$373K Sell
15,625
-2,211
-12% -$41.6K 0.03% 274
2025
Q2
$264K Buy
17,836
+36
+0.2% +$597 0.02% 288
2025
Q1
$319K Sell
17,800
-406
-2% -$8.24K 0.03% 282
2024
Q4
$317K Buy
18,206
+3,494
+24% +$61.8K 0.03% 292
2024
Q3
$206K Buy
14,712
+5,767
+64% +$60.1K 0.02% 297
2024
Q2
$73.5K Sell
8,945
-5,707
-39% -$38.4K 0.01% 321
2024
Q1
$113K Buy
14,652
+5,962
+69% +$50.3K 0.01% 362
2023
Q4
$78.1K Buy
8,690
+6,773
+353% +$49.3K 0.02% 313
2023
Q3
$17.1K Buy
1,917
+939
+96% +$13.3K 0.01% 309
2023
Q2
$15K Buy
978
+101
+12% +$1.84K ﹤0.01% 291
2023
Q1
$19.7K Buy
877
+225
+35% +$4.78K 0.01% 223
2022
Q4
$13.7K Buy
652
+53
+9% +$1.12K 0.01% 205
2022
Q3
$15K Buy
+599
New +$15.5K 0.01% 173

Other funds holding TVTX

China Universal Asset Management Company's TVTX Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Travere Therapeutics (TVTX) stake by 25% in Q2 2026, selling an estimated $223K and leaving 14,800 shares worth $841K. The position accounts for 0.05% of the portfolio, ranked #220.

China Universal Asset Management Company first reported a position in TVTX in Q3 2022 and has held it in 16 quarters since. 169 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • China Universal Asset Management Company held 14,800 shares of Travere Therapeutics worth $841K as of Q2 2026.
  • China Universal Asset Management Company sold 5,025 Travere Therapeutics shares in Q2 2026, an estimated $223K.
  • Travere Therapeutics made up 0.05% of China Universal Asset Management Company's portfolio in Q2 2026, its #220 holding.
  • China Universal Asset Management Company first reported a position in Travere Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • 169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.